haloperidol has been researched along with Marijuana Abuse in 9 studies
Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279)
haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.
Marijuana Abuse: Use of marijuana associated with abnormal psychological, social, and or occupational functioning.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We randomized cannabis users with active emesis to either haloperidol (with a nested randomization to either 0." | 9.41 | Intravenous Haloperidol Versus Ondansetron for Cannabis Hyperemesis Syndrome (HaVOC): A Randomized, Controlled Trial. ( Crawford, FM; Day, AG; Forrester, S; Hall, AK; Ruberto, AJ; Sivilotti, MLA, 2021) |
| "We randomized cannabis users with active emesis to either haloperidol (with a nested randomization to either 0." | 5.41 | Intravenous Haloperidol Versus Ondansetron for Cannabis Hyperemesis Syndrome (HaVOC): A Randomized, Controlled Trial. ( Crawford, FM; Day, AG; Forrester, S; Hall, AK; Ruberto, AJ; Sivilotti, MLA, 2021) |
| "As the pneumothorax was completely reabsorbed, no chest drains were inserted and the patient was transferred to our toxicological intensive care unit." | 1.34 | ["Usual" cannabis abuse producing an unusual incident]. ( Heppner, HJ; Schmitt, K; Sieber, C, 2007) |
| "Treatment of schizophrenia is often complicated by substance abuse." | 1.30 | Alcohol dependence and hospitalization in schizophrenia. ( Arana, GW; Gerding, LB; Labbate, LA; Measom, MO; Santos, AB, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (11.11) | 18.7374 |
| 1990's | 1 (11.11) | 18.2507 |
| 2000's | 2 (22.22) | 29.6817 |
| 2010's | 4 (44.44) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Ruberto, AJ | 1 |
| Sivilotti, MLA | 1 |
| Forrester, S | 1 |
| Hall, AK | 1 |
| Crawford, FM | 1 |
| Day, AG | 1 |
| Hernández-Ramos, I | 1 |
| Parra-Esquivel, P | 1 |
| López-Hernández, Á | 1 |
| Burillo-Putze, G | 1 |
| Hickey, JL | 1 |
| Witsil, JC | 1 |
| Mycyk, MB | 1 |
| Inayat, F | 1 |
| Virk, HU | 1 |
| Ullah, W | 1 |
| Hussain, Q | 1 |
| Makkos, Z | 1 |
| Fejes, L | 1 |
| Inczédy-Farkas, G | 1 |
| Kassai-Farkas, A | 1 |
| Faludi, G | 1 |
| Lazáry, J | 1 |
| Heppner, HJ | 1 |
| Sieber, C | 1 |
| Schmitt, K | 1 |
| Egashira, N | 1 |
| Ishigami, N | 1 |
| Mishima, K | 1 |
| Iwasaki, K | 1 |
| Oishi, R | 1 |
| Fujiwara, M | 1 |
| Watanabe, N | 1 |
| Moroji, T | 1 |
| Tada, K | 1 |
| Aoki, N | 1 |
| Gerding, LB | 1 |
| Labbate, LA | 1 |
| Measom, MO | 1 |
| Santos, AB | 1 |
| Arana, GW | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Droperidol on Prevention of Emesis From Cannabinoid Hyperemesis Syndrome[NCT05244460] | Phase 3 | 45 participants (Anticipated) | Interventional | 2021-12-02 | Recruiting | ||
| Haloperidol Versus Ondansetron for Cannabis Hyperemesis Syndrome (HaVOC): A Randomized Controlled Trial[NCT03056482] | Phase 4 | 33 participants (Actual) | Interventional | 2017-05-21 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for haloperidol and Marijuana Abuse
| Article | Year |
|---|---|
Intravenous Haloperidol Versus Ondansetron for Cannabis Hyperemesis Syndrome (HaVOC): A Randomized, Controlled Trial.
Topics: Administration, Intravenous; Adult; Antiemetics; Female; Haloperidol; Humans; Male; Marijuana Abuse; | 2021 |
Intravenous Haloperidol Versus Ondansetron for Cannabis Hyperemesis Syndrome (HaVOC): A Randomized, Controlled Trial.
Topics: Administration, Intravenous; Adult; Antiemetics; Female; Haloperidol; Humans; Male; Marijuana Abuse; | 2021 |
Intravenous Haloperidol Versus Ondansetron for Cannabis Hyperemesis Syndrome (HaVOC): A Randomized, Controlled Trial.
Topics: Administration, Intravenous; Adult; Antiemetics; Female; Haloperidol; Humans; Male; Marijuana Abuse; | 2021 |
Intravenous Haloperidol Versus Ondansetron for Cannabis Hyperemesis Syndrome (HaVOC): A Randomized, Controlled Trial.
Topics: Administration, Intravenous; Adult; Antiemetics; Female; Haloperidol; Humans; Male; Marijuana Abuse; | 2021 |
8 other studies available for haloperidol and Marijuana Abuse
| Article | Year |
|---|---|
[Spontaneuos pneumomediastinum secondary to cannabinoid hyperemesis syndrome].
Topics: Antiemetics; Cannabinoids; Capsaicin; Haloperidol; Humans; Male; Marijuana Abuse; Mediastinal Emphys | 2019 |
Haloperidol for treatment of cannabinoid hyperemesis syndrome.
Topics: Abdominal Pain; Adult; Antiemetics; Cannabinoids; Haloperidol; Humans; Male; Marijuana Abuse; Nausea | 2013 |
Is haloperidol the wonder drug for cannabinoid hyperemesis syndrome?
Topics: Adult; Antiemetics; Cannabinoids; Haloperidol; Humans; Male; Marijuana Abuse; Nausea; Syndrome; Trea | 2017 |
[Clinical characteristics of cannabis-induced schizophrenia spectrum disorder].
Topics: Adolescent; Adult; Aggression; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Diben | 2011 |
["Usual" cannabis abuse producing an unusual incident].
Topics: Adolescent; Antipsychotic Agents; Dyspnea; Eye Hemorrhage; Haloperidol; Humans; Male; Marijuana Abus | 2007 |
Delta9-Tetrahydrocannabinol-induced cognitive deficits are reversed by olanzapine but not haloperidol in rats.
Topics: Acetylcholine; Animals; Antipsychotic Agents; Behavior, Animal; Benzodiazepines; Cognition Disorders | 2008 |
A therapeutic trial of caerulein to a long-term heavy marihuana user with amotivational syndrome.
Topics: Adult; Brief Psychiatric Rating Scale; Ceruletide; Drug Therapy, Combination; Haloperidol; Humans; M | 1984 |
Alcohol dependence and hospitalization in schizophrenia.
Topics: Adult; Alcoholism; Antipsychotic Agents; Cocaine-Related Disorders; Comorbidity; Female; Fluphenazin | 1999 |